AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsAbbVie generates billions in annual free cash flow and continues to expand its market share in immunology treatments.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.